Simulations Plus SLP MonolixSuite TM — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Simulations Plus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Simulations Plus’s 10-K, filed December 1, 2025, on SEC EDGAR. View the filing →
Ask your AI about Simulations Plus's monolixsuite tm — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Simulations Plus's monolixsuite TM — revenue?
- Simulations Plus (SLP) reported monolixsuite TM — revenue of $2.34M in Q2 2025.
- How has Simulations Plus's monolixsuite TM — revenue changed year-over-year?
- Simulations Plus's monolixsuite TM — revenue increased by 13.6% year-over-year, from $2.06M to $2.34M.
- What is the long-term trend for Simulations Plus's monolixsuite TM — revenue?
- Over 2 years (2023 to 2025), Simulations Plus's monolixsuite TM — revenue has grown at a 16.5% compound annual growth rate (CAGR), from $6.9M to $9.36M.
- What does monolixsuite TM — revenue mean?
- This metric represents the total gross revenue generated specifically from the licensing, maintenance, and associated services of the MonolixSuite software platform. It serves as a key indicator of the product's market adoption and its contribution to the company's overall software segment performance. Tracking this revenue stream helps investors assess the commercial success and growth trajectory of the company's specialized pharmaceutical modeling and simulation tools.